B Group, Inc.
- SEC CIK
- 0002043476
- Latest filing
- Aug 14, 2026
Holdings in Q2 2025
Holdings as of Jun 30, 2025, filed Aug 14, 2025. Long positions only; changes compare share counts with Q1 2025.
- Positions
- 15
- −2 vs. Q1 2025
- Portfolio value
- $115.8M
- +$697.5K (+0.6%) vs. Q1 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ADMAAdma Biologics, Inc. | COM | 2,317,542 | $42.2M | 36.4% | 00.0% | Unchanged | History |
| INSMINSMED Inc | COM PAR $.01 | 155,000 | $15.6M | 13.5% | −107,500−41.0% | Reduced | History |
| ZLABZai Lab Ltd | ADR | 400,000 | $14.0M | 12.1% | 00.0% | Unchanged | History |
| AKROAkero Therapeutics, Inc. | COM | 232,446 | $12.4M | 10.7% | −10,054−4.1% | Reduced | History |
| CLLSCellectis S.A. | SPON ADS | 3,256,501 | $4.97M | 4.3% | 00.0% | Unchanged | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 1,800,556 | $4.16M | 3.6% | +545,000+43.4% | Added | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 110,000 | $4.00M | 3.5% | +62,500+131.6% | Added | History |
| SGHTSight Sciences, Inc. | COM | 930,000 | $3.84M | 3.3% | +96,400+11.6% | Added | History |
| AURAAura Biosciences, Inc. | COM | 572,576 | $3.58M | 3.1% | +100,000+21.2% | Added | History |
| ASMBAssembly Biosciences, Inc. | COM NEW | 189,350 | $3.43M | 3.0% | −10,650−5.3% | Reduced | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 1,500,000 | $2.58M | 2.2% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 35,000 | $1.52M | 1.3% | +5,000+16.7% | Added | History |
| PRAXPraxis Precision Medicines, Inc. | COM NEW | 35,000 | $1.47M | 1.3% | +16,000+84.2% | Added | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 80,000 | $1.20M | 1.0% | +10,000+14.3% | Added | History |
| ORKAOruka Therapeutics, Inc. | COM | 75,000 | $840.8K | 0.7% | +16,785+28.8% | Added | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| Lilly Eli & Co532457958 | PUT | $11.7M | – |
| Ultragenyx Pharmaceutical IN90400D908 | CALL | – | $2.46M |
Sold out since Q1 2025 (2)
Positions held at the end of Q1 2025 that are gone from this filing.